EUCTR2017-001599-46-Outside-EU/EEA进行中（未招募）1 期
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Diagnosed with GAD on clinical exam as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and supported by the Mini International Neuropsychiatric Interview for children and adolescents (MINI-Kid).
- •- Diagnosis of moderate or greater severity of GAD as determined by the following:
- •Presence of 4 or more symptoms identified on the generalized anxiety subsection of the Pediatric Anxiety Rating Scale (PARS) symptom checklist at screening and randomization. Two of which are excessive worry and dread or fearful anticipation (nonspecific),
- •PARS severity score of 15 or more at screening and randomization for symptoms identified on the generalized anxiety subsection of PARS symptom checklist at screening and randomization,
- •Clinical Global Impressions of Severity (CGI-S) rating of 4 or more at screening and randomization,
- •Presence of significant social, academic, and/or familial dysfunction as determined by the Children's Global Assessment Scale (CGAS) score of 60 or less at screening and randomization.
- •- Female participants must test negative for pregnancy during screening Furthermore, female participants must agree to abstain from sexual activity or to use a reliable method of birth control as determined by the investigator during the study
- •- Participant's parent/legal representative and participant, if capable, are judged to be reliable by the investigator to keep all appointments for clinical visits, tests, and procedures required by the protocol
- •- Participant's parent/legal representative and participant, if capable, must have a degree of understanding such that they can communicate intelligently with the investigator and study coordinator
- •- Participants must be capable of swallowing study drug whole (without opening the capsule, crushing, dissolving, dividing, et cetera)
- •- Participants must have venous access sufficient to allow blood sampling and are compliant with blood draws as per the protocol
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 281
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Current diagnosis of major depressive disorder (MDD)
- •- Participants for whom the primary focus of treatment is separation anxiety or social phobia (participants with secondary separation anxiety or social phobia are allowed to participate)
- •- Have current primary diagnosis of any DSM-IV-TR Axis I disorder except GAD, or a current secondary DSM-IV-TR Axis 1 disorder that requires any pharmacologic treatment (other than those disorders listed below). Primary is defined as the disorder that is the primary focus of treatment
- •- Have a history of DSM-IV-TR-defined substance abuse or dependence within the past year, excluding caffeine and nicotine
- •- Have a current or previous diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, or pervasive development disorder, as judged by the investigator
- •- Have 1 or more first-degree relatives (parents or siblings) with diagnosed bipolar I disorder
- •- Have a serious or unstable medical illness, psychological condition, clinically significant laboratory or electrocardiogram (ECG) result, hypersensitivity to duloxetine, or its active ingredients, frequent or severe allergic reactions to multiple medications, uncontrolled narrow-angle glaucoma, acute liver injury (for example, hepatitis) or severe cirrhosis (Child-Pugh Class C), or a history of any seizure disorder (other than febrile seizures)
- •- Have a significant suicide attempt within 1 year of screening or are currently at risk of suicide in the opinion of the investigator
- •- Have initiated, stopped, or changed the type or intensity of psychotherapy within 6 weeks prior to screening. Participants who require a change to psychotherapy between weeks 1 through 10 will be excluded
- •- Have a weight less than 20 kilograms at any time during the screening period
- •- Female participants who are pregnant, nursing or have recently given birth
研究者
相似试验
进行中（未招募）
1 期
A study to determine the safety and efficacy of duloxetine in the treatment of children and adolescents with depression.MedDRA version: 20.0Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2017-001598-18-Outside-EU/EEAEli Lilly and Company Limited463
进行中（未招募）
不适用
A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorderEUCTR2008-006492-71-DEEli Lilly and Company336
进行中（未招募）
1 期
A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorderMajor depressive disorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2008-006492-71-FREli Lilly and Company336
进行中（未招募）
不适用
A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorderMajor depressive disorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2008-006492-71-EEEli Lilly and Company336
进行中（未招募）
不适用
A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorderMajor depressive disorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2008-006492-71-FIEli Lilly and Company336